“Biogen’s anticompetitive conduct, and the PBMs’ participation in it, delayed and substantially diminished the sale of generic Tecfidera in the United States, and unlawfully enabled Biogen to sell Tecfidera and Vumerity at artificially inflated units and prices,” according to the allegations in three complaints accusing Biogen of monopolizing the multiple sclerosis drug market.

Click Here To Read The Full Article